Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia

被引:0
作者
Stelmach, Piotr [1 ,2 ]
Blonski, Jerzy Z. [1 ,2 ]
Wawrzyniak, Ewa [1 ,2 ]
Schweiger, Pawel [3 ,4 ]
Wilandt, Artur [3 ]
Majak, Pawel [5 ]
Robak, Tadeusz [1 ,2 ]
机构
[1] Med Univ Lodz, Dept Hematol, Copernicus Mem Hosp, Lodz, Poland
[2] Copernicus Mem Hosp, Lodz, Poland
[3] Genloxa, Rzucewo, Poland
[4] Univ Gdansk, Dept Biotechnol & Mol Med, Gdansk, Poland
[5] Med Univ Lodz, Barlicki Univ Hosp, Dept Internal Med Asthma & Allergy, Lodz, Poland
来源
POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ | 2016年 / 70卷
关键词
17p13; deletion; beta(2)-microglobulin; chronic lymphocytic leukemia; prognostic factors; thymidine kinase; SERUM DEOXYTHYMIDINE KINASE; BINET STAGE; DISEASE; CLL; BETA-2-MICROGLOBULIN; CLASSIFICATION; PROGRESSION; LYMPHOMA; SURVIVAL; IDENTIFY;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Thymidine kinase (TK) activity is a marker of biological activity that allows the indolent and aggressive forms of chronic lymphocytic leukemia (CLL) to be distinguished. The aims of the study were to determine the relationship between TK activity and clinical status and prognosis, as well as to compare its activity with that of other prognostic and predictive factors. TK activity was measured in patient sera at the time of diagnosis using the DiviTum method, with the mean value being 439 Du/L. A correlation was found between TK activity and risk of disease progression (p=0.045). The optimal discriminative value of TK activity in the prediction of CLL progression was found to be 600 Du/L. TK activity significantly differed between the patients who achieved complete remission and those who only partially responded to therapy. In 93% of patients without any response to treatment and 18 out of 20 patients with progressive disease, TK activity over 600 Du/L was noted. In addition, all of the 10 patients with 17p13 deletion displayed TK activity of over 600 Du/L (p=0.0004). High TK activity also correlated with elevated levels of LDH (p=0.001) and beta(2)-microglobulin (p=0.03) in the study group. The results of the study indicated the importance of TK activity as a prognostic factor in patients with CLL.
引用
收藏
页码:1321 / 1330
页数:10
相关论文
共 33 条
[1]  
Alegre MM, 2014, ANTICANCER RES, V34, P2145
[2]  
[Anonymous], CHRON LYMPH LEUK STA
[3]  
[Anonymous], PRAKT LEK
[4]   Analysis of thymidine kinase serum levels by novel method DiviTum™ in multiple myeloma and monoclonal gammopathy of undetermined significance - comparison with imaging methods 99mTc-MIBI scintigraphy and 18F-FDG PET/CT [J].
Bacovsky, Jaroslav ;
Myslivecek, Miroslav ;
Minarik, Jiri ;
Scudla, Vlastimil ;
Pika, Tomas ;
Zapletalova, Jana ;
Petrova, Pavla ;
Bartkova, Margita ;
Adam, Tomas ;
Gronowitz, Simon J. .
BIOMEDICAL PAPERS-OLOMOUC, 2015, 159 (01) :135-138
[5]  
BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO
[6]  
2-V
[7]   Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine [J].
Di Raimondo, F ;
Giustolisi, R ;
Lerner, S ;
Cacciola, E ;
O'Brien, S ;
Kantarjian, H ;
Keating, MJ .
ANNALS OF ONCOLOGY, 2001, 12 (05) :621-625
[8]   THE USE OF SERUM DEOXYTHYMIDINE KINASE AS A PROGNOSTIC MARKER, AND IN THE MONITORING OF PATIENTS WITH NON-HODGKINS LYMPHOMA [J].
GRONOWITZ, JS ;
HAGBERG, H ;
KALLANDER, CFR ;
SIMONSSON, B .
BRITISH JOURNAL OF CANCER, 1983, 47 (04) :487-495
[9]  
Hallek M, 1999, BLOOD, V93, P1732
[10]   Serum beta 2-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma [J].
Hallek, M ;
Wanders, L ;
Ostwald, M ;
Busch, R ;
Senekowitsch, R ;
Stern, S ;
Schick, HD ;
KuhnHallek, I ;
Emmerich, B .
LEUKEMIA & LYMPHOMA, 1996, 22 (5-6) :439-447